HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blistex acquires $20 mil. Stri-Dex acne line from Bayer.

This article was originally published in The Rose Sheet

Executive Summary

BLISTEX ADDING $20 MIL. STRI-DEX ACNE BRAND to its OTC business with the acquisition of the line from Bayer. The purchase of the Stri-Dex acne treatment line from Bayer's Consumer Care division, announced March 11, gives Oakbrook, Ill.-based Blistex an 8.1% dollar share, or a fourth place slot, in the $254 mil. combined acne remedy market in U.S. food, drug and mass merchandise outlets, according to Chicago-based Information Resources, Inc. data for the 52 weeks ended Jan. 28.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002612

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel